Exelixis Inc

NASDAQ:EXEL  
21.81
-0.03 (-0.14%)
Products, Strategic Combinations, Regulatory

Exelixis Inc Says Storm To Deliver Small Molecule ADAR1 Clinical Candidate Compounds

Published: 10/14/2021 12:13 GMT
Exelixis Inc (EXEL) - Exelixis and Storm Therapeutics Enter Into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel Rna Modifying Enzymes.
Exelixis Inc - Storm to Deliver Small Molecule Adar1 Clinical Candidate Compounds.
Exelixis Inc - Under Terms of Agreement, Exelixis Will Pay Storm an Upfront Fee of $17 Million.
Exelixis Inc - Storm Will Be Eligible for Development, Regulatory and Commercialization Milestones, As Well As Tiered Royalties.